Patrick David Hsu
Principal Investigator and Salk Fellow at Salk Institute for Biological Studies
Patrick D. Hsu is a Principal Investigator and Salk Helmsley Fellow at the Salk Institute for Biological Studies. He received his B.A. from the University of California, Berkeley, as well as A.M. and Ph.D. degrees from Harvard University.
Working with Feng Zhang at the Broad Institute of MIT and Harvard and the McGovern Institute for Brain Research at MIT, he contributed to the early development of CRISPR-Cas9 genome engineering technologies for efficient and precise application in eukaryotic cells. As a lead scientist at Editas Medicine, Patrick also directed preclinical discovery projects to translate genome editing tools for the treatment of human genetic disorders. He has been recognized for these contributions by Forbes’ 30 Under 30 and a $1M NIH Director’s Early Independence Award.
At the Salk, the Hsu lab develops diverse approaches from synthetic biology, genomics, and neuroscience for the high-throughput interrogation and control of transcriptional and epigenetic cell states, particularly for the treatment of neurodegenerative disease and complex genetic disorders.
Every cure has a starting point. The Salk Institute embodies Jonas Salk’s mission to dare to make dreams into reality. Its internationally renowned and award-winning scientists explore the very foundations of life, seeking new understandings in neuroscience, genetics, immunology, plant biology and more. The Institute is an independent nonprofit organization and
architectural landmark: small by choice, intimate by nature and fearless in the face of any challenge. Be it cancer or Alzheimer’s, aging or diabetes, Salk is where cures begin.